| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
47,900,000 |
| Market
Cap: |
53.65(M) |
| Last
Volume: |
92,722 |
Avg
Vol: |
374,904 |
| 52
Week Range: |
$1.04 - $2.66 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P SMALLCAP 600 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Enzo Biochem is a diagnostics, clinical lab, and life sciences company. Co.'s operating segments include: Enzo Clinical Lab, which is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies; Enzo Life Sciences, which manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide; Enzo Therapeutics, which is a biopharmaceutical venture that has developed multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, various of which are derived from the work of Enzo Life Sciences.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
417,900 |
| Total Buy Value |
$0 |
$0 |
$0 |
$873,769 |
| Total People Bought |
0 |
0 |
0 |
5 |
| Total Buy Transactions |
0 |
0 |
0 |
14 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kasten Bernard L |
Director |
– • – |
2014-10-23 |
4 |
S |
$4.91 |
$16,684 |
D/D |
(3,400) |
55,282 |
|
- |
|
| Kasten Bernard L |
Director |
– • – |
2014-07-16 |
4 |
D |
$4.95 |
$78,455 |
D/D |
(15,698) |
64,847 |
|
- |
|
| Kasten Bernard L |
Director |
– • – |
2014-04-10 |
4 |
D |
$4.17 |
$31,275 |
D/D |
(7,500) |
80,545 |
|
- |
|
| Kasten Bernard L |
Director |
– • – |
2014-04-02 |
4 |
D |
$4.39 |
$21,960 |
D/D |
(5,000) |
88,045 |
|
- |
|
| Kasten Bernard L |
Director |
– • – |
2014-03-31 |
4 |
D |
$3.99 |
$9,985 |
D/D |
(2,500) |
93,045 |
|
- |
|
| Crescenzo Andrew R. |
Senior VP of Finance |
• – – |
2013-12-17 |
4 |
D |
$2.41 |
$19,280 |
D/D |
(8,000) |
52,452 |
|
- |
|
| Perlysky Dov |
Director |
– • – |
2012-09-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
600,826 |
|
- |
|
| Perlysky Dov |
Director |
– • – |
2012-09-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,964 |
|
- |
|
| Goldberg David C |
VP CorpDev IGM Enz Clin Labs |
• – – |
2012-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
87,316 |
|
- |
|
| Crescenzo Andrew R. |
Senior VP of Finance |
• – – |
2012-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
64,584 |
|
- |
|
| Whiteley Andrew P |
COO, Enzo Life Sciences, Inc. |
• – – |
2012-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
27,213 |
|
- |
|
| Rabbani Elazar |
CEO and Secretary |
• • – |
2011-11-16 |
4 |
B |
$2.28 |
$45,717 |
D/D |
20,000 |
2,120,289 |
2.81 |
- |
|
| Weiner Barry W |
Pres, CFO, Princ AO and Treasr |
• • – |
2011-11-16 |
4 |
S |
$2.25 |
$45,725 |
D/D |
(20,000) |
1,312,206 |
|
- |
|
| Whiteley Andrew P |
VP BusDev-COO Enzo Lif Sci Inc |
• – – |
2011-06-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,000 |
|
- |
|
| Bass Herbert B |
VP of Finance |
• – – |
2011-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
209,359 |
|
- |
|
| Goldberg David C |
VP CorpDev Pres Enz Clin Labs |
• – – |
2011-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
123,934 |
|
- |
|
| Whiteley Andrew P |
VP BusDev-COO Enzo Lif Sci Inc |
• – – |
2011-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
22,213 |
|
- |
|
| Crescenzo Andrew R. |
Senior VP of Finance |
• – – |
2011-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
0 |
|
- |
|
| Balezentis Carl W |
Pres., Enzo Life Sciences |
• – – |
2010-12-15 |
4 |
S |
$5.12 |
$65,147 |
D/D |
(12,724) |
25,950 |
|
- |
|
| Kent Stephen B H |
Director |
– • – |
2010-10-22 |
4 |
S |
$4.28 |
$34,432 |
D/D |
(8,000) |
9,654 |
|
- |
|
| Kent Stephen B H |
Director |
– • – |
2010-08-05 |
4 |
S |
$4.46 |
$11,179 |
D/D |
(2,500) |
17,654 |
|
- |
|
| Kent Stephen B H |
Director |
– • – |
2010-06-11 |
4 |
S |
$4.24 |
$21,471 |
D/D |
(5,000) |
20,154 |
|
- |
|
| Balezentis Carl W |
Pres., Enzo Life Sciences |
• – – |
2010-04-07 |
4 |
S |
$6.23 |
$187 |
D/D |
(30) |
35,724 |
|
- |
|
| Kent Stephen B H |
Director |
– • – |
2010-03-15 |
4 |
S |
$6.12 |
$30,742 |
D/D |
(5,000) |
25,154 |
|
- |
|
| Krenitsky Kevin |
President, Enzo Clinical Labs |
• – – |
2010-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
17,600 |
|
- |
|
264 Records found
|
|
Page 5 of 11 |
|
|
0.03 (2.75%) 
